Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.49 |
| ▸ | NPY1R | P25929 | 10/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.49 |
| ▸ | NPY2R | P49146 | 6/20 | 0.49 |
| ▸ | Q9HBH1 | 1/20 | 0.46 | |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799804 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RPDF | |
| SCHEMBL1694104 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RPDF | |
| Hydrochloric Acid SCHEMBL1259758 | 0.99 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RPDF | |
| Hydrochloric Acid SCHEMBL6703991 | 0.99 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RPDF | |
| SCHEMBL8089028 | 0.92 | PDF (0.47) | NPY4RNPY1RNPY5RNPY2RPDF | |
| SCHEMBL11374268 | 0.88 | PDF (0.49) | NPY4RNPY1RNPY5RNPY2RPDF | |
| SCHEMBL8723156 | 0.88 | PDF (0.52) | NPY4RNPY1RNPY5RNPY2RPDF | |
| 4-Nitroaniline SCHEMBL11127406 | 0.87 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| 4-Nitroaniline SCHEMBL10711897 | 0.87 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL5756647 | 0.87 | PDF (0.45) | NPY4RNPY1RNPY5RNPY2RPDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740938-A1 | PREPARATION METHOD FOR KLK1 FUSION PROTEIN | ALEBUND PHARMACEUTICALS (HONG KONG) LIMITED (HK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4037687-B1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-120137951-A | Recombinant human kininogenase mutant and application thereof | 北京华大蛋白质研发中心有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119546286-A | Preparation method of KLK1 fusion protein | 礼邦医药(香港)有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-114615984-B | Benzoxazinone compounds as dual KLK5/7 inhibitors | 分子皮肤治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025007838-A1 | PREPARATION METHOD FOR KLK1 FUSION PROTEIN | 礼邦医药(香港)有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4037687-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | Molecular Skin Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-0458903-A1 | SOLUBLE ANALOGS OF THROMBOMODULIN | CODON (US) | 1991-12-04 | — | — | EP | disclosed |
| WO-1991015514-A1 | OXIDATION RESISTANT THROMBOMODULIN ANALOGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-10-17 | — | — | WO | disclosed |
| WO-1990010081-A1 | SOLUBLE ANALOGS OF THROMBOMODULIN | CODON (US) | 1990-09-07 | — | — | WO | disclosed |
| EP-0365568-A1 | PROTEINS AND DERIVATIVES THEREOF | NOVO NORDISK A/S (DK) | 1990-05-02 | — | — | EP | disclosed |
| EP-0352227-A2 | Modified proteins | CIBA-GEIGY AG (CH) | 1990-01-24 | — | — | EP | disclosed |
| EP-0352228-A2 | Novel proteins | CIBA-GEIGY AG (CH) | 1990-01-24 | — | — | EP | disclosed |
| US-4835253-A | LOW MOLECULAR WEIGHT KININOGEN ANALOGS | THE UNIVERSITY HOSPITAL (US) | 1989-05-30 | — | — | US | disclosed |
| WO-1988009811-A1 | PROTEINS AND DERIVATIVES THEREOF | NOVO-NORDISK A/S (DK) | 1988-12-15 | — | — | WO | disclosed |
| US-4595674-A | Pharmaceuticals | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-17 | — | — | US | disclosed |
| US-4234477-A | DIAGNOSTIC DETERMINATION OF A HYDROLASE, CALLICREIN | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | NPY4R 1425/4885NPY1R 1052/4885NPY5R 705/4885 |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | NPY4R 1425/4885NPY1R 1052/4885NPY5R 705/4885 |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | KLK5, KLK1, KLK2 | NPY4R 1425/4885NPY1R 1052/4885NPY5R 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.